Clinical evidence of the effectiveness of vinpocetine in the treatment of organic psychosyndrome

This study was multi-center, double-blind, placebo controlled, and involved random assignment of patients. It was carried out in the ambulances of general practitioners and internists. The aim of the study was to evaluate the efficacy and tolerance of vinpocetine in patients with a mild to moderate severe organic psychosyndrome caused by cerebral blood supply disorders and / or metabolic disturbance. Dosage of 5, 10 and 20 mg vinpocetine or placebo t.i.d. Were examined over a treatment period of 12 weeks with 282 patients.

The study design required a programmed, standardized investigator training. In addition, a pre-study test was used to ensure correct and uniform execution of study control.

The Clinical Global Impression (CGI) and the performance test SKT showed statistically significant differences between the verum groups and placebo. Self-assessment of mood and performance capability (EDS), and life satisfaction (LZ) confirmed these outcomes. The results of the Hachinski Ischaemia Scores did not permit an unequivocal classification of patients into primary degenerative and multi-infarct dementia types. The higher dosage groups experienced a greater therapeutic advantage than did the 5 mg t.i.d vinpocetine dosage group. Only a few side effects were observed.